Idera Pharmaceuticals, Inc. (IDRA): Price and Financial Metrics
GET POWR RATINGS... FREE!
IDRA Stock Price Chart Interactive Chart >
IDRA Price/Volume Stats
|Current price||$0.42||52-week high||$1.04|
|Prev. close||$0.40||52-week low||$0.30|
|Day high||$0.43||Avg. volume||494,902|
|50-day MA||$0.44||Dividend yield||N/A|
|200-day MA||$0.49||Market Cap||22.49M|
Idera Pharmaceuticals, Inc. (IDRA) Company Bio
Idera Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of novel therapeutics for oncology and rare diseases in the United States. The company was founded in 1989 and is based in Cambridge, Massachusetts.
Most Popular Stories View All
IDRA Latest News Stream
|Loading, please wait...|
IDRA Latest Social Stream
View Full IDRA Social Stream
Latest IDRA News From Around the Web
Below are the latest news stories about IDERA PHARMACEUTICALS INC that investors may wish to consider to help them evaluate IDRA as an investment opportunity.
Idera Pharmaceuticals Inc (NASDAQ: IDRA) acquired Aceragen Inc, a privately-held biotechnology company focused on rare, orphan pulmonary, and rheumatic diseases. The combined cash of the two companies is expected to provide a runway into Q3 2023, funding the advancement of Aceragen's pipeline, including ACG-701 and ACG-801, through important 2023 clinical milestones. The company estimates an annual peak sales potential of $650 million from the three current lead programs. Vincent Milano, Idera's
Acquisition includes late-stage rare disease portfolio with anticipated 2023 clinical milestones and first potential product approval as early as late 2024 Conference call and webcast today at 5:00 p.m. ET EXTON, Pa. and DURHAM, N.C., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” or “our”) (Nasdaq: IDRA) today announced it has completed the acquisition of Aceragen, Inc. (“Aceragen”), a privately-held biotechnology company addressing rare, orp
EXTON, Pa., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” or “our”) (Nasdaq: IDRA) today reported its financial and operational results for the second quarter ended June 30, 2022. Second Quarter Financial Results Our cash position as of June 30, 2022 was $24.5 million. Based on our current operating plan, we anticipate that our current cash and cash equivalents will fund our operations through the one-year period subsequent to the August 9, 20
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Idera Pharmaceuticals Inc (NASDAQ: IDRA) shared positive interim results from its investigator-sponsored Phase 2 trial, INTRIM 1, involving tilsotolimod, Idera's synthetic Toll-like receptor 9 agonist. Based on these results, the trial has been stopped early. The trial included patients with localized, excised melanoma (pathological tumor stage 3-4) with no regional metastases detected and no evidence of distant metastasis. Noting that there were more patients with ulcerated lesions in the place
IDRA Price Returns
Continue Researching IDRAWant to see what other sources are saying about Idera Pharmaceuticals Inc's financials and stock price? Try the links below:
Idera Pharmaceuticals Inc (IDRA) Stock Price | Nasdaq
Idera Pharmaceuticals Inc (IDRA) Stock Quote, History and News - Yahoo Finance
Idera Pharmaceuticals Inc (IDRA) Stock Price and Basic Information | MarketWatch